(Q37127231)

18 August 2017

1 reference

title

Getting to the stem of chronic myeloid leukaemia (English)

1 reference

18 August 2017

1 reference

Michael Robert Savona

series ordinal

1

object named as

Michael Savona

1 reference

18 August 2017

Moshe Talpaz

2

1 reference

PubMed ID

18385684

18 August 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

18 August 2017

Nature Reviews Cancer

1 reference

18 August 2017

8

1 reference

18 August 2017

341-350

1 reference

18 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc2368

18 August 2017

0 references

cites work

BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis

1 reference

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance

21 January 2018

1 reference

BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?

21 January 2018

1 reference

Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

21 January 2018

1 reference

SOCS proteins: negative regulators of cytokine signaling

31 March 2020

1 reference

The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf.

31 March 2020

1 reference

Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis

31 March 2020

1 reference

Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway

31 March 2020

1 reference

Critical role for Gab2 in transformation by BCR/ABL

31 March 2020

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

31 March 2020

1 reference

The Role of cis-Platinum in Solid-Tumor Therapy

31 March 2020

1 reference

Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?

31 March 2020

1 reference

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

31 March 2020

1 reference

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

31 March 2020

1 reference

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

31 March 2020

1 reference

Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.

31 March 2020

1 reference

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

31 March 2020

1 reference

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

31 March 2020

1 reference

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

31 March 2020

1 reference

Discontinuation of imatinib therapy after achieving a molecular response

31 March 2020

1 reference

CML cytogenetic relapse after cessation of imatinib therapy

31 March 2020

1 reference

Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib

31 March 2020

1 reference

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

31 March 2020

1 reference

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

31 March 2020

1 reference

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

31 March 2020

1 reference

Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia

31 March 2020

1 reference

Haematopoietic stem cells do not asymmetrically segregate chromosomes or retain BrdU.

31 March 2020

1 reference

The purification and characterization of fetal liver hematopoietic stem cells.

31 March 2020

1 reference

Searching for hematopoietic stem cells: evidence that Thy-1.1lo Lin- Sca-1+ cells are the only stem cells in C57BL/Ka-Thy-1.1 bone marrow

31 March 2020

1 reference

SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells

31 March 2020

1 reference

The Biology of Hematopoietic Stem Cells

31 March 2020

1 reference

Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice

31 March 2020

1 reference

Assay of human stem cells by repopulation of NOD/SCID mice

31 March 2020

1 reference

Individual stem cells with highly variable proliferation and self-renewal properties comprise the human hematopoietic stem cell compartment.

31 March 2020

1 reference

Isolation of a candidate human hematopoietic stem-cell population

31 March 2020

1 reference

Interleukin-1 and tumor necrosis factor alpha induce class 1 aldehyde dehydrogenase mRNA and protein in bone marrow cells

31 March 2020

1 reference

Low rhodamine 123 retention identifies long-term human hematopoietic stem cells within the Lin-CD34+CD38- population.

31 March 2020

1 reference

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

31 March 2020

1 reference

Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML.

31 March 2020

1 reference

Leukaemia stem cells and the evolution of cancer-stem-cell research.

31 March 2020

1 reference

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

31 March 2020

1 reference

Stem cells, cancer, and cancer stem cells

31 March 2020

1 reference

Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity.

31 March 2020

1 reference

Prospective identification of tumorigenic breast cancer cells

31 March 2020

1 reference

Cancer stem cells in nervous system tumors

31 March 2020

1 reference

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

31 March 2020

1 reference

Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma

31 March 2020

1 reference

Identification of pancreatic cancer stem cells

31 March 2020

1 reference

Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)

31 March 2020

1 reference

An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.

31 March 2020

1 reference

Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells

31 March 2020

1 reference

Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage

31 March 2020

1 reference

Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level

31 March 2020

1 reference

Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias

31 March 2020

1 reference

Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

31 March 2020

1 reference

Mechanisms controlling pathogenesis and survival of leukemic stem cells

31 March 2020

1 reference

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies

31 March 2020

1 reference

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

31 March 2020

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

31 March 2020

1 reference

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro

31 March 2020

1 reference

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

31 March 2020

1 reference

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

31 March 2020

1 reference

Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.

31 March 2020

1 reference

Evolving molecular therapy for chronic myeloid leukaemia--are we on target?

31 March 2020

1 reference

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

31 March 2020

1 reference

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib

31 March 2020

1 reference

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

31 March 2020

1 reference

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

31 March 2020

1 reference

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

31 March 2020

1 reference

Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib

31 March 2020

1 reference

Overriding imatinib resistance with a novel ABL kinase inhibitor

31 March 2020

1 reference

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells

31 March 2020

1 reference

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

31 March 2020

1 reference

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

31 March 2020

1 reference

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

31 March 2020

1 reference

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

31 March 2020

1 reference

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

31 March 2020

1 reference

Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.

31 March 2020

1 reference

Dynamics of chronic myeloid leukaemia.

31 March 2020

1 reference

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

31 March 2020

1 reference

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

31 March 2020

1 reference

Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.

31 March 2020

1 reference

Cancer. Addiction to oncogenes--the Achilles heal of cancer

31 March 2020

1 reference

"Oncogenic shock": explaining oncogene addiction through differential signal attenuation

31 March 2020

1 reference

A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes

31 March 2020

1 reference

BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells

31 March 2020

1 reference

p38 Mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest

31 March 2020

1 reference

Role of the p38 MAPK pathway in cisplatin-based therapy

31 March 2020

1 reference

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up

31 March 2020

1 reference

Requirement of Src kinase Lyn for induction of DNA synthesis by granulocyte colony-stimulating factor.

31 March 2020

1 reference

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia

31 March 2020

1 reference

A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency

31 March 2020

1 reference

Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment

31 March 2020

1 reference

Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells

31 March 2020

1 reference

Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age

31 March 2020

1 reference

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

31 March 2020

1 reference

MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.

31 March 2020

1 reference

31 March 2020

1 reference

MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice

31 March 2020

1 reference

The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia

31 March 2020

1 reference

Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM.

31 March 2020

1 reference

Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia.

31 March 2020

1 reference

Wnt signalling in stem cells and cancer

31 March 2020

1 reference

Diversity of LEF/TCF action in development and disease

31 March 2020

1 reference

Hematopoietic stem cell and multilineage defects generated by constitutive β-catenin activation

31 March 2020

1 reference

Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block.

31 March 2020

1 reference

From the yolk sac to the spleen: New roles for Notch in regulating hematopoiesis

31 March 2020

1 reference

Notch1 expression in early lymphopoiesis influences B versus T lineage determination.

31 March 2020

1 reference

TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms

31 March 2020

1 reference

Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells

31 March 2020

1 reference

Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells

31 March 2020

1 reference

Definitive hematopoiesis requires the mixed-lineage leukemia gene

31 March 2020

1 reference

Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells.

31 March 2020

1 reference

Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells

31 March 2020

1 reference

High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia

31 March 2020

1 reference

Diverse effects of the Notch ligands Jagged1 and Delta1 on the growth and differentiation of primary acute myeloblastic leukemia cells.

31 March 2020

1 reference

Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression

31 March 2020

1 reference

Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth

31 March 2020

1 reference

Raf-independent deregulation of p38 and JNK mitogen-activated protein kinases are critical for Ras transformation

31 March 2020

1 reference

Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation

31 March 2020

1 reference

MAPKAP kinase 3pK phosphorylates and regulates chromatin association of the polycomb group protein Bmi1

31 March 2020

1 reference

The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia.

31 March 2020

1 reference

Chronic myeloid leukaemia as a model of disease evolution in human cancer

31 March 2020

1 reference

Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors

31 March 2020

1 reference

Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies

31 March 2020

1 reference

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC2368

1 reference

PubMed ID

18385684

Dimensions Publication ID

18 August 2017

0 references

1 reference

PubMed ID

18385684